Table 1.
Overview of FDA-approved monoclonal antibody therapies (adapted from 29)
| Antibody | Conjugate | Subtype | Brand name | Target |
|---|---|---|---|---|
| Cetuximab | – | Mouse/human chimeric IgG1 | Erbitux® | EGFR |
| Panitumumab | – | Human IgG2 | Vectibix® | EGFR |
| Trastuzumab | – | Humanized IgG1 | Herceptin® | HER-2 |
| Bevacizumab | – | Humanized IgG1 | Avastin® | VEGF |
| Ipilimumab | – | Human IgG1 | Yervoy® | CTLA-4 |
| Rituximab | – | Mouse/human chimeric IgG1 | Rituxan®/MabThera® | CD20 |
| Ofatumumab | – | Human IgG1 | Arzerra® | CD20 |
| 90Y-Ibritumomab Tiuxetan | 90Yttrium | Murine IgG1 | Zevalin® | CD20 |
| 131I-Tositumomab | 131Iodine | Murine IgG2 | Bexxar® | CD20 |
| Brentuximab Vedotin | Monomethyl auristatin E | Mouse/human chimeric IgG1 | Adcetris® | CD30 |
| Gemtuzumab Ozogamicin | Ozogamicin | Humanized IgG4 | Mylotarg® | CD33 |
| Alemtuzumab | – | Humanized IgG1 | Campath® | CD52 |